Dragon Pharma Helios 5.8 mg is an oil-based injectable product supplied in a 10 mL vial containing a blend of Clenbuterol HCl and Yohimbine HCl at a total labeled strength of 5.8 mg/mL. Product specifications, a published lab report, storage information, and other practical product details are provided below.
5.8 mg/mL Strength
Total labeled concentration of 5.8 mg per mL, combining two active substances.
10 mL Vial
Supplied as an oil-based injectable solution in a sealed multidose vial.
Combination Formula
Blends a beta-2 agonist (Clenbuterol) with an alpha-2 antagonist (Yohimbine).
Published Lab Report
A published lab report provides measured results for the tested batch.
Product Specifications
Product name
Helios 5.8 mg
Active substances
Clenbuterol HCl, Yohimbine HCl
Labeled strength
Clenbuterol: 80 mcg/mL · Yohimbine: 5 mg/mL
Total labeled content
5.8 mg/mL
Container
10 mL vial
Total labeled amount
800 mcg Clenbuterol · 50 mg Yohimbine
Product form
Oily solution (MCT Oil)
Manufacturer
Dragon Pharma
Published Test Result
The latest published report for batch #HELIBG9, dated November 20, 2025, measured 43.28 mcg/mL for Clenbuterol and 5.27 mg/mL for Yohimbine against the stated concentrations. Open the Lab Reports tab to view the full report.
Related Products
Other products in the Dragon Pharma range include the standalone Clenbuterol and the beta-3 agonist Salbutamol.
Each product has a distinct mechanism of action and is studied for its specific biological activity.
Published Testing
Dragon Pharma Helios 5.8 mg Lab Reports
A published lab report for Dragon Pharma Helios 5.8 mg is provided below with the test date, measured results and reported batch number. Each result can be compared directly with the product's labeled strength of 80 mcg/mL for Clenbuterol and 5 mg/mL for Yohimbine.
Helios combines Clenbuterol HCl, a beta-2 adrenergic agonist, with Yohimbine HCl, an alpha-2 adrenergic antagonist. This combination is used for its synergistic effects on lipolysis and thermogenesis.
1
Clenbuterol (Beta-2 Agonist)
Clenbuterol is a sympathomimetic amine that acts as a beta-2 adrenergic agonist. It has thermogenic and bronchodilatory properties.
2
Yohimbine (Alpha-2 Antagonist)
Yohimbine is an alpha-2 adrenergic receptor antagonist. It is thought to facilitate lipolysis by blocking the inhibitory effect of alpha-2 receptors on fat cells.
3
Synergistic Effect
The combination of these two substances is designed to enhance lipolysis and fat oxidation through complementary mechanisms.
Mechanisms of Action
Clenbuterol is a beta-2 adrenergic agonist that stimulates the sympathetic nervous system, leading to increased metabolic rate and thermogenesis. Yohimbine is an alpha-2 adrenergic receptor antagonist that blocks the inhibitory effect of alpha-2 receptors on fat cells. This is thought to facilitate the release of fatty acids from adipose tissue for oxidation.
The product is supplied as an oil-based injectable solution at a total labeled strength of 5.8 mg/mL.
Distinct Mechanisms
Clenbuterol and Yohimbine are not anabolic steroids or hormones. They are adrenergic compounds with mechanisms of action distinct from these substances, acting on the sympathetic nervous system and adrenergic receptors.
Medical and Research References
Clenbuterol is not approved for human use in the United States. Yohimbine is an FDA-approved prescription medication for certain indications. Official sources provide information on its pharmacology and safety considerations.
Sympathomimetic compounds can cause significant side effects and require appropriate medical monitoring. A laboratory report confirms information about the tested sample, but it does not determine whether use is safe or appropriate for an individual.
Cardiovascular Effects
Clenbuterol and Yohimbine can increase heart rate and blood pressure. This can be particularly important for individuals with existing cardiovascular conditions.
Tremors and Nervousness
Beta-2 agonists like Clenbuterol are associated with tremors, nervousness, and anxiety. These effects are generally dose-dependent.
Electrolyte and Metabolic Effects
Clenbuterol may cause potassium depletion and changes in blood glucose levels. Monitoring may be appropriate during use.
Stimulant Effects
Both compounds are stimulants and may cause insomnia, restlessness, and gastrointestinal discomfort. Avoid use late in the day to minimize sleep disruption.
Medical Consultation
Discussing any new product, including sympathomimetic compounds, with a healthcare professional is recommended before use.
Conditions That Require Medical Review
Medical advice is particularly important when there is a history of cardiovascular disease, hypertension, arrhythmias, hyperthyroidism, glaucoma, or psychiatric conditions.
Pregnancy and breastfeeding are also important considerations for these compounds. The product should be stored securely to prevent accidental access or use by children or other household members.
When to Seek Urgent Medical Help
Seek urgent medical attention for symptoms such as chest pain, severe palpitations, sudden shortness of breath, fainting, signs of an allergic reaction, or any rapidly worsening symptoms.
Tested Sport
Clenbuterol is prohibited under anti-doping rules in tested sport. Yohimbine is not currently prohibited but is on the monitoring program. The current status and applicable rules can be checked through the World Anti-Doping Agency Prohibited List.
Common Product Questions
Dragon Pharma Helios 5.8 mg FAQ
Quick answers about Helios 5.8 mg specifications, the published lab report, storage, shipping, Bitcoin payment, and general product information.
What is Dragon Pharma Helios 5.8 mg?
Dragon Pharma Helios 5.8 mg is an oil-based injectable product containing a blend of Clenbuterol HCl and Yohimbine HCl at a total labeled strength of 5.8 mg/mL. It is supplied in a 10 mL vial.
What are the active substances in Helios?
Each mL contains 80 mcg of Clenbuterol HCl and 5 mg of Yohimbine HCl.
How much of each substance is in a full vial?
A 10 mL vial contains a total of 800 mcg of Clenbuterol and 50 mg of Yohimbine.
What did the latest lab report show?
The published report, dated November 20, 2025, measured 43.28 mcg/mL for Clenbuterol (54.10% of label) and 5.27 mg/mL for Yohimbine (105.40% of label) for batch #HELIBG9.
Does a lab report verify every vial?
No. Each report applies to the sample submitted for that specific test and the batch identified in the report. It does not independently verify the content or condition of every individual vial.
How should Helios 5.8 mg be stored?
Keep the vial in its original packaging and follow the storage directions printed on the label. Protect it from excessive heat, moisture and direct light, and keep it securely out of reach of children and pets.
Does Helios 5.8 mg contain hormones?
No. Helios contains Clenbuterol (a beta-2 agonist) and Yohimbine (an alpha-2 antagonist), which are not anabolic steroids or hormones.
Is Helios permitted in tested sport?
Clenbuterol is prohibited under anti-doping rules. Yohimbine is on the monitoring program. The current status should be checked against the relevant anti-doping rules before competition.
How long does Helios 5.8 mg delivery take?
Delivery depends on the warehouse selected for the order. Shipments from the USA Warehouse typically take 4β5 business days after dispatch, while shipments from the International Warehouse typically take 15β20 business days after dispatch. Full delivery and reship information is available on the Shipping Information page.
Can I buy Helios 5.8 mg with Bitcoin?
Yes. Bitcoin and other supported cryptocurrencies are available at checkout for all orders. To buy Helios 5.8 mg with Bitcoin, select Bitcoin as the payment method during checkout and follow the payment instructions provided with the order.
Is Bitcoin payment anonymous?
Bitcoin transactions are recorded on a public blockchain and should not be considered automatically anonymous. Accurate order and delivery information is still required for order processing and shipping.
Where can I find official safety information for these substances?
Yohimbine is FDA-approved and has official prescribing information. Clenbuterol is not approved for human use in the United States. Relevant resources are provided in the Science & Research and Safety sections above.